|
Monoclonal antibodies: 2009 update
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 237 seiten | |||||||||
| Inhalt der Studie: |
Introduction
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2014 and assessing trends by product, company, therapy.....
Introduction The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2014 and assessing trends by product, company, therapy area, geography, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics. Scope *Comprehensive financial strategic analysis of the mAb market out to 2014 *Global sales forecasts to 2014 for marketed and Phase III mAb products *Analysis of market trends by product, company, geography, therapy area, technology and target type *Analysis of characteristics of key products and insight into direction of mAb technology evolution and pipeline dynamics Highlights The global prescription pharmaceutical market is expected to face a decline in sales over 2012 to 2013 as a result of the 'patent cliff'. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth. Over the forecast period monoclonal antibodies are predicted to enjoy double-digit growth while small molecule drugs face declining growth rates. The main barrier to sales growth for small molecules, and particularly in the US, is exposure to material generic competition, which Datamonitor believes will have no effect on mAbs out to 2014. This attractive growth rate and sales return potential has made mAb companies a prime acquisition target in recent years, even during a period of economic uncertainty, with a number of key acquisitions made during 2008-09. Reasons to Purchase *Assess the key products that will drive sales growth in the mAb market to 2014 *Identify the key geographic regions of the global mAb market and the dynamics within these territories *Understand the challenges and barriers to entry for new players seeking to venture into the mAb market Report Highlights [Studien Infos ausblenden] |
|||||||||||
|
ABOUT DATAMONITOR HEALTHCARE 2 About the PharmaVitae team 2 Chapter 1 About this Sector Report 3 PharmaVitae Explorer database 3 Chapter structure 3 Executive summary 3 mAb technology overview 3 Market analysis 3 Pipeline analysis 4 Key products 4 Data sourcing 4 Sales data 4 Chapter 2 Executive summary 5 Key findings 5 Total prescription pharmaceutical market outlook 5 Monoclonal antibody market outlook 6 Introduction to the PharmaVitae company universe 7 The prescription pharmaceutical market to 2014 10 Prescription pharmaceutical market performance, 2008-14 10 Introduction to molecule type analysis 11 Small molecules 12 Therapeutic proteins 12 Monoclonal antibodies 12 Vaccines 12 Industry consequences of molecule type 12 Prescription pharmaceutical sales by molecule type, 2008-14 14 The monoclonal antibody market will deliver the biggest portion of sales growth across the entire pharmaceutical industry, at the fastest rate 14 The mAb market is forecast to increase at a double-digit growth rate 17 The monoclonal antibody market will deliver much-needed sales growth in order to offset US-centered small molecule sales collapse 18 Geographic sales growth: the US and 5EU lead the way 21 A raft of new mAbs expected to make it onto the market over 2008-14... 24 ...but still only a few mAbs command the highest revenues 25 Introduction to the 'Big 5' 26 'Big 5' dominance will remain, although their share will decline 27 Product analysis (size) 28 Product analysis (growth) 29 Company analysis 31 Big Pharma's hold on the mAb market 33 Recent M&A deals underline Pharma's 'bankable view' of mAbs 35 The mAb landscape: innovation driven by collaboration and M&A 37 Long term opportunities and threats 40 Long term threat of biosimilar mAbs? 40 The US offers the 'biggest biosimilar prize' 40 Price of mAb therapies a major resistor to growth, however, the collapse of the US branded small molecule market could 'free-up' payer resource to expand mAb purchasing 41 Drive for personalized medicine: the role of companion diagnostics, an opportunity for diagnostic and mAb players 41 Table of Contents 42 Table of figures 44 Chapter 3 MAb Technology Overview 45 Key findings 45 Introduction 46 The immune system 46 B lymphocytes and antibodies 46 Antibody structure 46 Hybridoma technique - the production of mAbs 48 Monoclonal antibodies as therapeutic agents 48 Targets 48 Target selection - the importance of an accessible epitope 49 Production of mAbs 49 Transgenic mice 49 Phage display 50 Future focus 50 Mode of action 51 mAb-focused oncology 51 The effect of the effector region 51 Blockade 51 MAbs as a delivery vehicle 52 Evolution of mAbs 52 Limitations associated with immunization 52 Murine 57 Chimeric and humanized antibodies 57 Chimeric 57 Humanized 58 Fully human 59 Fragments 59 Conjugated 60 Radiolabeled conjugated mAbs 60 Focus for antibody R&D - oncology immunotoxin drug conjugates 61 Naked mAbs still dominate 62 Systematic naming of monoclonal antibodies 63 The mAb timeline - technology evolution 63 Manufacturing 68 Time to market and manufacturing of monoclonal antibodies 68 Mammalian cell culture - still the most widely-used system 68 Chapter 4 Market analysis 72 Key findings 72 Introduction 73 The mAb market, overview of the fastest growing sector across the pharmaceutical industry 73 The mAb market: the double-digit growth market 75 Key global mAb products, 2002-14 75 Introduction to the 'Big 5' 76 MAb market: product analysis, 2002-14 77 Historical product analysis, 2002-08 79 Growth from a few 80 Rapid uptake from two key therapies 81 Growth continues from more established therapies 82 Forecast product analysis, 2008-14 84 Avastin to shape the mAb market future 86 Humira will be the biggest immunology & inflammation driver 87 Still growth left for the older brands 88 Exciting Amgen entrant to make an impact 89 Second generation anti-TNF to gain some ground on Humira... 89 ...at the expense of Remicade 90 Innovative Alzheimer's therapy attracts additional Big Pharma investment 90 Roche expands mAb interests away from oncology 91 MAb market: company analysis, 2002-14 92 Historical product analysis, 2002-08 93 'Big 5' ownership highlights four key players 94 Genentech and Roche: the symbiotic partnership 94 Abbott Laboratories, growth through in-licensing 95 Schering Plough and Johnson & Johnson: Remicade centered growth 95 Forecast company analysis, 2008-14 96 Leading players will maintain standing, with few new entrants 97 Roche through Genentech maintains leading position 98 Abbott's Humira-centric growth 98 Amgen: the emerging player 99 Johnson & Johnson, recent deal boosts mAb interests 99 MAb market: therapy area analysis, 2002-14 100 Historical therapy area analysis, 2002-08 101 'Big Three' drives oncology sales 102 Immunology & inflammation: two-product therapy area 103 Forecast therapy area analysis, 2008-14 103 Oncology: Genentech/Roche continue to lead the way 105 Immunology & inflammation delivers strong growth, despite Raptiva withdrawal 106 After a stuttering start central nervous system will emerge as a major mAb therapy area 107 Musculoskeletal 107 MAb market: geographic analysis, 2002-14 109 Historical geographic analysis, 2002-08 110 US growth centered on 'Big 5' 110 Herceptin drives 5EU sales 110 Japan: older therapies in an earlier life cycle stage 110 Forecast geographic analysis, 2008-14 111 The US and 5EU will contribute almost 80% of the global mAb market growth 112 The developing Japanese market will experience some major brand launches... 113 ... but the RoW will still generate more mAb sales 113 MAb market: technology analysis, 2002-14 114 Historical technology analysis, 2002-08 115 Humanized becomes the number one in 2008 115 Forecast technology analysis, 2008-14 116 Increasing human content the market driver 116 Avastin and key launch products will drive humanized sales 117 Human mAb sales growth centered on three products 118 The once dominant chimeric mAbs will slow in growth 118 Antibody fragments, the only other +$1 billion sales growth driver 119 MAb market: target analysis, 2002-14 120 Historical target analysis, 2002-08 121 Forecast target analysis, 2008-14 122 Avastin and Lucentis will drive VEGF sales 124 Well represented TNF alpha target will continue to grow 124 CD20: Rituxan remains dominant although GSK will make some headway 124 RANKL sales growth from highly anticipated first-in-class Prolia 125 Market withdrawal of Raptiva in 2009 ends CD11a sales growth 125 Chapter 5 Pipeline analysis 126 Key findings 126 Introduction 127 MAb pipeline overview 128 Company pipeline analysis 135 Late-stage company pipeline analysis 137 Early-stage company pipeline analysis 140 Change of direction driven by acquisition 141 Technology pipeline analysis 143 Therapy area pipeline analysis 147 Target pipeline analysis 150 Target crowding evident with the late-stage mAbs - with lifecycle management strategies being employed 151 Novel target early-stage candidates 153 Chapter 6 Key products 159 Key findings 159 Introduction 160 Oncology 161 Avastin 161 Overview 161 Sales forecast 162 Product overview 162 Additional indication approvals drives growth 162 Failure in adjuvant trial raises concerns 163 Competitive threats to future sales growth 164 Herceptin 165 Overview 165 Sales forecast 166 Product overview 166 Competitive threats to future sales growth 167 MabThera/Rituxan 169 Overview 169 Sales forecast 170 Product overview 170 Competitive threats to future sales growth 171 Erbitux 172 Overview 172 Sales forecast 173 Restrictive patient population impedes sales growth 173 Additional indications drive growth 174 Prolia (onco) 176 Overview 176 Sales forecast 177 Prolia (oncology) 177 Significant opportunity in oncology, targeting Zometa's market 177 Amgen initially seeking approval for treatment of bone loss in patients receiving hormone ablation chemotherapy 178 Biggest sales potential lies within the treatment and prevention of bone metastasis 178 Amgen announces positive late-stage bone metastases data 178 Vectibix 180 Overview 180 Sales forecast 181 Personalized medicine movement to boost sales? 181 Arzerra 183 Overview 183 Sales forecast 184 Genmab/GlaxoSmithKline are investigating Arzerra in the first-line follicular lymphoma setting 184 Genmab/GlaxoSmithKline's commercial strategy may improve Arzerra's chances of success in the non-Hodgkin's lymphoma market 184 Targeting underserved chronic lymphocytic leukemia patients may enhance Arzerra's uptake in the market; gains FDA approval 185 Immunology & inflammation 186 Humira 186 Overview 186 Sales forecast 187 First fully human anti-TNF alpha mAb 187 Aggressive indication broadening 187 Humira growth outstrips rivals Enbrel and Remicade 188 Significant dosing and delivery advantages help drive uptake 188 Further growth across all indications expected despite new launches 188 Remicade 189 Overview 189 Sales forecast 190 Remicade can be used at first-line without prior failure of methotrexate 190 Remicade is prescribed in patients who may have compliance problems 191 Unlike Enbrel and Humira, Remicade does not have the JIA indication 191 Remicade's sales will decrease from 2010 as patients shift to Simponi 191 Simponi 192 Overview 192 Sales forecast 193 Simponi will be positioned in multiple rheumatoid arthritis patient subgroups 193 Simponi and first-generation Remicade will compete in the same rheumatoid arthritis populations 193 Simponi offers dosing frequency advantages over other TNF inhibitors 194 Cimzia 196 Overview 196 Sales forecast 197 UCB's novel anti-TNF mAb finally gets green light 197 UCB faces a considerable promotional hurdle in recruiting physicians 197 Non-responder patient population and pricing offer key route to uptake 198 Actemra 199 Overview 199 Sales forecast 200 Product overview 200 Delay to launch in the US 201 Actemra has strong positioning potential as a result of impressive Phase III program 201 Product positioning 201 Future performance 201 Stelara 203 Overview 203 Sales forecast 204 Compared to Enbrel, Stelara shines in terms of efficacy 204 Dosing frequency distinguishes Stelara from marketed biologics 205 Central nervous system 206 Tysabri 206 Overview 206 Sales forecast 207 Product overview 207 Safety scare 207 Re-launch 208 Two new confirmed cases of PML rocks initially strong 2008 Tysabri uptake 208 Physician enrollment and patient numbers have increased strongly with each month through to July 2008 209 Long-term growth hinges on the incidence and management of new PML cases 209 Bapineuzumab 210 Overview 210 Sales forecast 211 Product overview 211 Campath (CNS) 213 Overview 213 Sales forecast 214 Product overview 214 Phase II data show superior efficacy compared to Rebif 214 Safety concerns 215 Future market potential 215 Infectious diseases 217 Numax 217 Overview 217 Sales forecast 218 Product overview 218 Synagis 219 Overview 219 Sales forecast 220 Product overview 220 Respiratory 221 Xolair 221 Overview 221 Sales forecast 222 Musculoskeletal 223 Prolia 223 Overview 223 Sales forecast 224 First-in-class therapy 224 Not oral, but convenient dosing all the same 225 Strong clinical trial data, issues regarding safety 225 Initially positioned as a second-line therapy 226 GSK deal should provide Amgen with higher returns 226 Cardiovascular 227 ReoPro 227 Overview 227 Sales forecast 228 Other 229 Lucentis 229 Overview 229 Sales forecast 230 Fragment of Avastin has provided significant revenues 230 Strong clinical trial data has positioned Lucentis as the market leading treatment 230 Avastin off-label usage discouraged 230 Chapter 7 Appendix 232 References 232 Datamonitor reports 232 Abbreviations 233 Exchange rates 234 About Datamonitor 235 About Datamonitor Healthcare 235 Datamonitor consulting 235 Disclaimer 237 List of Tables Table 1: PharmaVitae company coverage by peer set 8 Table 2: Molecule type definitions 11 Table 3: General characteristics of small molecule drugs vs. biologics 13 Table 4: Prescription pharmaceutical sales ($m) by molecule type, 2008-14 14 Table 5: The global small molecule market ($m), 2008-14 18 Table 6: The global mAb market ($m), 2008-14 20 Table 7: The 'Big 5' (annual revenues >$4 billion in both 2008 and 2014) 26 Table 8: Overview of a selection of marketed mAbs: technology type and immunogenicity 54 Table 9: Infix nomenclature for mAbs 63 Table 10: Manufacturing cell lines for marketed mAbs 70 Table 11: Global top 5: 2002, 2008 & 2014 ($m) 75 Table 12: The 'Big 5' (annual revenues >$4 billion in both 2008 and 2014) 76 Table 13: Historical mAb product sales ($m), 2002-08 79 Table 14: Forecast mAb product sales ($m), 2008-14 84 Table 15: Historical mAb company sales ($m), 2002-08 93 Table 16: Forecast mAb company sales ($m), 2008-14 96 Table 17: Historical mAb therapy area sales ($m), 2002-08 101 Table 18: Forecast mAb therapy area sales ($m), 2008-14 104 Table 19: Historical mAb geography sales ($m), 2002-08 110 Table 20: Forecast mAb geography sales ($m), 2008-14 111 Table 21: Historical mAb technology sales ($m), 2002-08 115 Table 22: Forecast mAb technology sales ($m), 2008-14 116 Table 23: Historical mAb target sales ($m), 2002-08 121 Table 24: Forecast mAb target sales ($m), 2008-14 122 Table 25: MAb pipeline overview 128 Table 26: Count of marketed mAbs 135 Table 27: Count of Phase III mAb players 137 Table 28: Count of companies with multiple Phase I-II mAb candidates 140 Table 29: mAb count split by technology type 143 Table 30: mAb count split by technology type 147 Table 31: Detailed product/target analysis - late stage 150 Table 32: Novel late-stage targets 152 Table 33: Novel early-stage targets 154 Table 34: Avastin: overview 161 Table 35: Avastin: sales forecast ($m), 2008-14 162 Table 36: Herceptin: overview 165 Table 37: Herceptin: sales forecast ($m), 2008-14 166 Table 38: MabThera/Rituxan: overview 169 Table 39: MabThera/Rituxan: sales forecast ($m), 2008-14 170 Table 40: Erbitux: overview 172 Table 41: Erbitux: sales forecast ($m), 2008-14 173 Table 42: Prolia (onco): overview 176 Table 43: Prolia (onco): sales forecast ($m), 2008-14 177 Table 44: Vectibix: overview 180 Table 45: Vectibix: sales forecast ($m), 2008-14 181 Table 46: Arzerra: overview 183 Table 47: Arzerra: sales forecast ($m), 2008-14 184 Table 48: Humira: overview 186 Table 49: Humira: sales forecast ($m), 2008-14 187 Table 50: Remicade: overview 189 Table 51: Remicade: sales forecast ($m), 2008-14 190 Table 52: Simponi: overview 192 Table 53: Simponi: sales forecast ($m), 2008-14 193 Table 54: Comparison of the route of administration and dosing frequency of the anti-TNFs in rheumatoid arthritis 194 Table 55: Cimzia: overview 196 Table 56: Cimzia: sales forecast ($m), 2008-14 197 Table 57: Actemra: overview 199 Table 58: Actemra: sales forecast ($m), 2008-14 200 Table 59: Stelara: overview 203 Table 60: Stelara: sales forecast ($m), 2008-14 204 Table 61: Tysabri: overview 206 Table 62: Tysabri: sales forecast ($m), 2008-14 207 Table 63: Bapineuzumab: overview 210 Table 64: Bapineuzumab: sales forecast ($m), 2008-14 211 Table 65: Campath (CNS): overview 213 Table 66: Campath (CNS): sales forecast ($m), 2008-14 214 Table 67: Numax: overview 217 Table 68: Numax: sales forecast ($m), 2008-14 218 Table 69: Synagis: overview 219 Table 70: Synagis: sales forecast ($m), 2008-14 220 Table 71: Xolair: overview 221 Table 72: Xolair: sales forecast ($m), 2008-14 222 Table 73: Prolia: overview 223 Table 74: Prolia: sales forecast ($m), 2008-14 224 Table 75: ReoPro: overview 227 Table 76: ReoPro: sales forecast ($m), 2008-14 228 Table 77: Lucentis: overview 229 Table 78: Lucentis: sales forecast ($m), 2008-14 230 Table 79: Exchange rates, 2009 234 List of Figures Figure 1: The PharmaVitae Explorer 3 Figure 2: The total pharmaceutical market outlook, sales ($m) and year-on-year growth rate (%), 2002-14 10 Figure 3: Change in annual sales from 2008-14 ($m) of PharmaVitae universe by molecule type 15 Figure 4: Compound annual growth rate (%) of PharmaVitae universe by molecule type 16 Figure 5: Total sales of the mAb market ($m), 2002-14 17 Figure 6: The US versus ex-US small molecule market sales growth ($m), (%), 2002-14 19 Figure 7: The US versus ex-US monoclonal antibody market sales growth ($m), (%), 2002-14 20 Figure 8: mAb market geographic analysis, total sales ($m), 2002-14 22 Figure 9: Total number of mAbs versus total mAb market sales ($m), 2002-14 24 Figure 10: Total mAb sales versus average price per mAb ($m), 2002-14 25 Figure 11: Sales proportion of the 'Big 5' vs the rest of the mAb market (%), 2002-14 27 Figure 12: mAb product sales ($m), 2002-14 28 Figure 13: Growth driver/resistor products of forecast revenue performance ($m), 2008-14 29 Figure 14: MAb company sales ($m), 2002-14 31 Figure 15: mAb ownership sales by peer set ($,%), 2002-14 33 Figure 16: Big Pharma's $74 billion worth of key mAb acquisitions over the past five years 35 Figure 17: The collaborative landscape of the mAb market key players 37 Figure 18: The structure of an antibody 47 Figure 19: Types of antibodies 53 Figure 20: Immunogenicity ranges 55 Figure 21: Number of marketed mAb technologies 56 Figure 22: Schematic illustration of antibody fragments 60 Figure 23: mAb timeline - technology shift 64 Figure 24: Total sales of the mAb market ($m), 2002-14 74 Figure 25: MAb product sales ($m), 2002-14 77 Figure 26: Growth driver/resistor products of historical revenue performance ($m), 2002-08 81 Figure 27: Growth driver/resistor products of forecast revenue performance ($m), 2008-14 86 Figure 28: MAb company sales ($m), 2002-14 92 Figure 29: Growth driver/resistor companies of historical revenue performance ($m), 2002-08 94 Figure 30: Growth driver/resistor companies of forecast revenue performance ($m), 2008-14 98 Figure 31: MAb therapy area sales ($m), 2002-14 100 Figure 32: Growth driver/resistor therapy areas of historical revenue performance ($m), 2002-08 102 Figure 33: Growth driver/resistor therapy areas of forecast revenue performance ($m), 2008-14 105 Figure 34: MAb geography sales ($m), 2002-14 109 Figure 35: Growth driver/resistor geographies of forecast revenue performance ($m), 2008-14 112 Figure 36: MAb technology sales ($m), 2002-14 114 Figure 37: Growth driver/resistor technologies of forecast revenue performance ($m), 2008-14 117 Figure 38: MAb target sales ($m), 2002-14 120 Figure 39: Growth driver/resistor targets of forecast revenue performance ($m), 2008-14 123 Figure 40: Count of marketed mAb players 136 Figure 41: Count of Phase III pipeline mAb players 138 Figure 42: Count of companies with multiple Phase I-II mAb candidates 141 Figure 43: Phase I-III pipeline count split by technology 144 Figure 44: The stepwise evolution of naked mAb technology 145 Figure 45: Overview of pipeline technology type Phase I-registration 146 Figure 46: Phase I-pre-reg mAb count split by therapy area 148 Figure 47: Count of the most popular targets in early-stage development 158 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Table 1: PharmaVitae company coverage by peer set 8 Table 2: Molecule type definitions 11 Table 3: General characteristics of small molecule drugs vs. biologics 13 Table 4: Prescription pharmaceutical sales ($m) by molecule type, 2008-14 14 Table 5: The global small molecule market ($m), 2008-14 18 Table 6: The global mAb market ($m), 2008-14 20 Table 7: The 'Big 5' (annual revenues >$4 billion in both 2008 and 2014) 26 Table 8: Overview of a selection of marketed mAbs: technology type and immunogenicity 54 Table 9: Infix nomenclature for mAbs 63 Table 10: Manufacturing cell lines for marketed mAbs 70 Table 11: Global top 5: 2002, 2008 & 2014 ($m) 75 Table 12: The 'Big 5' (annual revenues >$4 billion in both 2008 and 2014) 76 Table 13: Historical mAb product sales ($m), 2002-08 79 Table 14: Forecast mAb product sales ($m), 2008-14 84 Table 15: Historical mAb company sales ($m), 2002-08 93 Table 16: Forecast mAb company sales ($m), 2008-14 96 Table 17: Historical mAb therapy area sales ($m), 2002-08 101 Table 18: Forecast mAb therapy area sales ($m), 2008-14 104 Table 19: Historical mAb geography sales ($m), 2002-08 110 Table 20: Forecast mAb geography sales ($m), 2008-14 111 Table 21: Historical mAb technology sales ($m), 2002-08 115 Table 22: Forecast mAb technology sales ($m), 2008-14 116 Table 23: Historical mAb target sales ($m), 2002-08 121 Table 24: Forecast mAb target sales ($m), 2008-14 122 Table 25: MAb pipeline overview 128 Table 26: Count of marketed mAbs 135 Table 27: Count of Phase III mAb players 137 Table 28: Count of companies with multiple Phase I-II mAb candidates 140 Table 29: mAb count split by technology type 143 Table 30: mAb count split by technology type 147 Table 31: Detailed product/target analysis - late stage 150 Table 32: Novel late-stage targets 152 Table 33: Novel early-stage targets 154 Table 34: Avastin: overview 161 Table 35: Avastin: sales forecast ($m), 2008-14 162 Table 36: Herceptin: overview 165 Table 37: Herceptin: sales forecast ($m), 2008-14 166 Table 38: MabThera/Rituxan: overview 169 Table 39: MabThera/Rituxan: sales forecast ($m), 2008-14 170 Table 40: Erbitux: overview 172 Table 41: Erbitux: sales forecast ($m), 2008-14 173 Table 42: Prolia (onco): overview 176 Table 43: Prolia (onco): sales forecast ($m), 2008-14 177 Table 44: Vectibix: overview 180 Table 45: Vectibix: sales forecast ($m), 2008-14 181 Table 46: Arzerra: overview 183 Table 47: Arzerra: sales forecast ($m), 2008-14 184 Table 48: Humira: overview 186 Table 49: Humira: sales forecast ($m), 2008-14 187 Table 50: Remicade: overview 189 Table 51: Remicade: sales forecast ($m), 2008-14 190 Table 52: Simponi: overview 192 Table 53: Simponi: sales forecast ($m), 2008-14 193 Table 54: Comparison of the route of administration and dosing frequency of the anti-TNFs in rheumatoid arthritis 194 Table 55: Cimzia: overview 196 Table 56: Cimzia: sales forecast ($m), 2008-14 197 Table 57: Actemra: overview 199 Table 58: Actemra: sales forecast ($m), 2008-14 200 Table 59: Stelara: overview 203 Table 60: Stelara: sales forecast ($m), 2008-14 204 Table 61: Tysabri: overview 206 Table 62: Tysabri: sales forecast ($m), 2008-14 207 Table 63: Bapineuzumab: overview 210 Table 64: Bapineuzumab: sales forecast ($m), 2008-14 211 Table 65: Campath (CNS): overview 213 Table 66: Campath (CNS): sales forecast ($m), 2008-14 214 Table 67: Numax: overview 217 Table 68: Numax: sales forecast ($m), 2008-14 218 Table 69: Synagis: overview 219 Table 70: Synagis: sales forecast ($m), 2008-14 220 Table 71: Xolair: overview 221 Table 72: Xolair: sales forecast ($m), 2008-14 222 Table 73: Prolia: overview 223 Table 74: Prolia: sales forecast ($m), 2008-14 224 Table 75: ReoPro: overview 227 Table 76: ReoPro: sales forecast ($m), 2008-14 228 Table 77: Lucentis: overview 229 Table 78: Lucentis: sales forecast ($m), 2008-14 230 Table 79: Exchange rates, 2009 234 List of Figures Figure 1: The PharmaVitae Explorer 3 Figure 2: The total pharmaceutical market outlook, sales ($m) and year-on-year growth rate (%), 2002-14 10 Figure 3: Change in annual sales from 2008-14 ($m) of PharmaVitae universe by molecule type 15 Figure 4: Compound annual growth rate (%) of PharmaVitae universe by molecule type 16 Figure 5: Total sales of the mAb market ($m), 2002-14 17 Figure 6: The US versus ex-US small molecule market sales growth ($m), (%), 2002-14 19 Figure 7: The US versus ex-US monoclonal antibody market sales growth ($m), (%), 2002-14 20 Figure 8: mAb market geographic analysis, total sales ($m), 2002-14 22 Figure 9: Total number of mAbs versus total mAb market sales ($m), 2002-14 24 Figure 10: Total mAb sales versus average price per mAb ($m), 2002-14 25 Figure 11: Sales proportion of the 'Big 5' vs the rest of the mAb market (%), 2002-14 27 Figure 12: mAb product sales ($m), 2002-14 28 Figure 13: Growth driver/resistor products of forecast revenue performance ($m), 2008-14 29 Figure 14: MAb company sales ($m), 2002-14 31 Figure 15: mAb ownership sales by peer set ($,%), 2002-14 33 Figure 16: Big Pharma's $74 billion worth of key mAb acquisitions over the past five years 35 Figure 17: The collaborative landscape of the mAb market key players 37 Figure 18: The structure of an antibody 47 Figure 19: Types of antibodies 53 Figure 20: Immunogenicity ranges 55 Figure 21: Number of marketed mAb technologies 56 Figure 22: Schematic illustration of antibody fragments 60 Figure 23: mAb timeline - technology shift 64 Figure 24: Total sales of the mAb market ($m), 2002-14 74 Figure 25: MAb product sales ($m), 2002-14 77 Figure 26: Growth driver/resistor products of historical revenue performance ($m), 2002-08 81 Figure 27: Growth driver/resistor products of forecast revenue performance ($m), 2008-14 86 Figure 28: MAb company sales ($m), 2002-14 92 Figure 29: Growth driver/resistor companies of historical revenue performance ($m), 2002-08 94 Figure 30: Growth driver/resistor companies of forecast revenue performance ($m), 2008-14 98 Figure 31: MAb therapy area sales ($m), 2002-14 100 Figure 32: Growth driver/resistor therapy areas of historical revenue performance ($m), 2002-08 102 Figure 33: Growth driver/resistor therapy areas of forecast revenue performance ($m), 2008-14 105 Figure 34: MAb geography sales ($m), 2002-14 109 Figure 35: Growth driver/resistor geographies of forecast revenue performance ($m), 2008-14 112 Figure 36: MAb technology sales ($m), 2002-14 114 Figure 37: Growth driver/resistor technologies of forecast revenue performance ($m), 2008-14 117 Figure 38: MAb target sales ($m), 2002-14 120 Figure 39: Growth driver/resistor targets of forecast revenue performance ($m), 2008-14 123 Figure 40: Count of marketed mAb players 136 Figure 41: Count of Phase III pipeline mAb players 138 Figure 42: Count of companies with multiple Phase I-II mAb candidates 141 Figure 43: Phase I-III pipeline count split by technology 144 Figure 44: The stepwise evolution of naked mAb technology 145 Figure 45: Overview of pipeline technology type Phase I-registration 146 Figure 46: Phase I-pre-reg mAb count split by therapy area 148 Figure 47: Count of the most popular targets in early-stage development 158 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
